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Abstract
Background: Migraine affects approximately 20% of the population. Conventional care for migraine is suboptimal; overuse of
medications for the treatment of episodic migraines is a risk factor for developing chronic daily headache. The study of non-
pharmaceutical approaches for prevention of migraine headaches is therefore warranted. Craniosacral therapy (CST) is a
popular non-pharmacological approach to the treatment or prevention of migraine headaches for which there is limited evidence
of safety and efficacy. In this paper, we describe an ongoing feasibility study to assess the safety and efficacy of CST in the
treatment of migraine, using a rigorous and innovative randomized controlled study design involving low-strength static magnets
(LSSM) as an attention control intervention.
Methods: The trial is designed to test the hypothesis that, compared to those receiving usual care plus a treatment with low-
strength static magnets (attention-control complementary therapy), subjects receiving usual medical care plus CST will
demonstrate significant improvement in: quality-of-life as measured by the Headache Impact Test (HIT-6); reduced frequency of
migraine; and a perception of clinical benefit. Criteria for inclusion are either gender, age > 11, English or Spanish speaking,
meeting the International Classification of Headache Disorders (ICHD) criteria for migraine with or without aura, a headache
frequency of 5 to 15 per month over at least two years. After an 8 week baseline phase, eligible subjects are randomized to
either CST or an attention control intervention, low strength static magnets (LSSM). To evaluate possible therapist bias,
videotaped encounters are analyzed to assess for any systematic group differences in interactions with subjects.
Results: 169 individuals have been screened for eligibility, of which 109 were eligible for the study. Five did not qualify during
the baseline phase because of inadequate headache frequency. Nineteen have withdrawn from the study after giving consent.
Conclusion: This report endorses the feasibility of undertaking a rigorous randomized clinical trial of CST for migraine using
a standardized CST protocol and an innovative control protocol developed for the study. Subjects are able and willing to
complete detailed headache diaries during an 8-week baseline period, with few dropouts during the study period, indicating the
acceptability of both interventions.
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Background
Migraine affects approximately 20 percent of the adult
population, developing in the second and third decades
and often persisting into late middle age and beyond
[1,2]. Although the pathophysiology is not fully under-
stood, there are clearly genetic, vascular and neural mech-
anisms involved [3]. Frequency and duration are highly
variable and the onset is said to be triggered at times by
stress, history of head or neck trauma, certain foods and
hormonal changes in women [4-6]. Symptoms can be dif-
ficult to control and quality of life may deteriorate sub-
stantially.
Management includes modification of diet, and recom-
mendations for sleep, exercise, and stress reduction
through bio-behavioral interventions as well as the use of
a range of medications for prevention and acute treatment
of migraine. Many of these medications are associated
with significant side effects [7,8]. Furthermore, overuse of
medications for the treatment of episodic migraines is a
risk factor for developing chronic daily headache [9]. The
study of non-pharmacological interventions for the treat-
ment or prevention of migraine headaches is therefore
warranted. Because conventional care for migraine is sub-
optimal, many individuals seek alternative treatment
options [10,11].
Craniosacral therapy (CST) is one popular non-pharma-
cological approach to the treatment or prevention of
migraine headaches for which there is limited evidence of
safety and efficacy.
CST involves manually identifying restrictions in the
craniosacral system which includes the bones, mem-
branes and cerebrospinal fluid (CSF) that surround the
brain and spinal cord, and using soft, gentle hands-on
techniques to both normalize the CST fluid rhythm and
correct restrictions in perispinal tissues and fascia [12].
Manual palpation and manipulation of this system theo-
retically affects sensory, motor, cognitive and emotional
processes in the nervous system [12-15].
CST is often used as adjunctive therapy by physical thera-
pists, osteopathic physicians, chiropractors and massage
therapists. It is purported to reduce the use of conven-
tional pain medications and improve daily functioning in
a variety of conditions [16]. To our knowledge, there are
no reports in the conventional medical literature of the
use of CST for migraine, either alone or in combination
with standard medical care. Several reports of CST in gen-
eral headache suggest the possibility of significant benefit
for some patients, including reduction of intensity of
pain, reduction in medication use and improved function
[16,17]. These reports suffer from a lack of specific head-
ache diagnoses and poor documentation of how CST was
integrated with conventional care. Criteria for diagnosis,
numbers of treatments, co-morbid conditions, psychoso-
cial status, coping strategies for pain, prior trauma, quali-
fications of the practitioner, longitudinal follow-up, and
changes in quality-of-life and overall function are not
reported. Moreover, these study designs lack control
groups and randomization.
In this paper, we describe an ongoing feasibility study to
assess the safety and efficacy of CST in the treatment of
migraine. This is the first rigorous approach to the study
of CST for migraine. The aims of the study are as follows:
1) To determine the feasibility of developing a clinical
trial comparing usual medical care plus craniosacral ther-
apy (CST) versus usual medical care and low-strength
static magnet therapy (LSSM – attention-control) as treat-
ments for the prevention of migraine;
2) To identify relevant secondary outcomes associated
with usual care plus adjunctive CST; and
3) To identify and find solutions for potential problems in
conducting a future large clinical trial to assess the efficacy
of CST for the prevention of migraine.
Methods
Study Design
The study examines the feasibility of a randomized con-
trolled trial that compares CST to low strength static mag-
nets (LSSM). Figure 1 illustrates the overall design and
subject flow through the study. Study procedures and con-
sent forms were reviewed and approved by the Institu-
tional Review Board of the University of North Carolina.
Hypothesis
The trial is designed to test the hypothesis that, compared
to those receiving usual care plus a treatment with low-
strength static magnets (attention-control complementary
therapy), subjects receiving usual medical care plus CST
will demonstrate significant improvement in: quality-of-
life as measured by the Headache Impact Test (HIT-6), a
headache-specific quality-of-life measure; reduced fre-
quency of migraine; and a perception of clinical benefit.
Eligibility
Criteria for inclusion are: individuals of either gender, age
12 and above, English or Spanish speaking, meeting the
International Classification of Headache Disorders
(ICHD) criteria for migraine with or without aura, a head-
ache frequency of 5 to 15 per month and a history of at
least two years of migraine (Table 1). The rationale for
headache frequency criteria is that patients with more
than 5 headaches per month could be considered to have
failed conventional therapy, especially if function is sig-BMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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nificantly impaired, while those with more than 15 head-
aches per month are considered to have chronic migraine
and may be physiologically different than those with epi-
sodic migraine [18]. Children are included because
migraine is a significant problem in children, with limita-
tions in pharmacologic approaches [19].
Recruitment, selection and randomization flow diagram for the clinical feasibility trial of craniosacral therapy (CST), 2006–2008 Figure 1
Recruitment, selection and randomization flow diagram for the clinical feasibility trial of craniosacral therapy 
(CST), 2006–2008
Telephone screen for eligibility (Expected n = 240)
Expected to be ineligible = 140
Headache characteristics 
Other medical exclusions 
No physician 
Scheduling difficulties 
First confirmation of eligibility 
Baseline study visit with neurologist (PI)
Consent for study, begin baseline diary collection
Baseline instruments (HIT-6, MIDAS, SF-36)
Second confirmation of eligibility 
Baseline diaries reviewed
Expected to be randomized = 70
Expected to be excluded  = 6
Headache characteristics 
Unstable co-morbid conditions 
Medications 
Allocate to craniosacral therapy 
CST = 8 weekly 45-minute treatments
Assessment at beginning of therapy (HIT-6)
Collection of diary data continues
Follow-up assessment at end of therapy
(HIT-6, Diary data)
Expected withdrawal = 5
Allocate to magnet therapy 
LSSM = 8 weekly 45-minute treatments
Assessment at beginning of therapy (HIT-6)
Collection of diary data continues
ITT analysis of diary and HIT-6 data
Expected n = 30
ITT analysis of diary and HIT-6 data
Expected n = 30
Follow-up assessment 4 weeks post
(MIDAS, SF-36, Diary data)
Quality control assessment of intervention
Follow-up assessment at end of therapy
(HIT-6, Diary data)
Expected withdrawal = 5
Follow-up assessment 4 weeks post
(MIDAS, SF-36,Diary Data) 
Quality control assessment of intervention
Expected to be excluded = 24
Failure to keep diaries 
Headache characteristics 
Other intervening problems BMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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Exclusion criteria include marked depression, anxiety or
psychosis; more than two visits/month for mental health
care; more than one psychiatric medication; major medi-
cal illness under treatment; pregnancy; clotting disorders;
recent head or neck trauma within two years, and pres-
ence of a cardiac pacemaker or other implanted or exter-
nal electrical device (see Table 1). While there is no
evidence that CST or magnet therapy would harm either
the mother or the fetus, the frequency of migraine is often
affected by hormonal fluxes such as during and following
pregnancy [20]. Hence, women were excluded who were
pregnant, nursing, or initiating hormone replacement
therapy. Those with mental illness requiring multiple
medications, and those with diagnoses of major depres-
sion, anxiety or psychosis, were excluded because of the
requirement of detailed daily diary completion as well as
the effects of active mental illness in exacerbating
migraine. To increase the believability of the LSSM inter-
vention, those with cardiac pacemaker or other electrical
devices were excluded, even though it was unlikely that
the extremely low-strength magnets would affect these
devices.
Recruitment
Subjects are recruited from the following sources: 1) Uni-
versity of North Carolina (UNC) Headache Clinic; 2)
local neurology practices; 3) local primary care clinics; 4)
broadcast email to UNC students and employees; and 5)
advertisements in the regional press. Subjects receive eight
sessions of CST or magnet therapy at no cost. They are
reimbursed for completing their diaries and question-
naires up to a maximum of $170 for the entire study.
Recruitment and study materials are available in both
Spanish and English. Hispanic subjects are recruited
through advertisements in Spanish-language newspapers
and through clinics serving the Hispanic community. A
Spanish interpreter is available for help with consenting
and to accompany subjects at each treatment session.
The recruitment strategy has been intentionally broad, tar-
geting headache specialty care, primary care and non-care
populations with migraine to avoid missing qualifying
subjects and to include subjects with differing levels of
care and a range of migraine symptoms. Although
migraine is a common disorder, many sufferers either do
not seek medical attention or, when they do, are not
treated for migraine [21,22]. Random digit surveys of the
general public suggest that less than 50% of those with
migraine are currently seeing a physician for that problem
[23]. Therefore, limiting recruitment to those under active
medical care for migraine would potentially eliminate
more than half the eligible individuals from considera-
tion. In addition, only a small subset of migraine patients
seek specialty care; these individuals may be fundamen-
tally different from the global population of migraine
patients [21]. Limiting recruitment to those individuals
would restrict the pool of potential subjects.
Screening, consent, and enrollment
Those interested in being part of the study contact the
research staff for a telephone screening interview. Those
identified through the screening process as potentially eli-
gible subjects are scheduled to meet with the study coor-
dinator for the consenting process and to undergo a
baseline medical assessment, including a complete medi-
cal history and physical examination by the study neurol-
ogist. The study neurologist confirms the diagnosis of
migraine and excludes from the study those individuals
with other medical problems that could put the patient at
risk or confound the study results, e.g., recent head
trauma, untreated or uncontrolled hypertension, diabe-
tes, or depression. Excluded patients are referred back to
their physicians for further medical management.
Enrolled subjects are asked to avoid changes in medica-
tions, dietary supplements, and non-pharmacologic treat-
ments for headache during the course of the study.
Table 1: Eligibility of Subjects for Clinical Feasibility Trial of Craniosacral Therapy, 2006–2008
Inclusion Criteria Exclusion Criteria
Subjects > 11 years of age Marked depression, anxiety or psychosis
Either gender More than 2 visits/month for mental health care
Meet ICHD* criteria for migraine More than one psychiatric medication
Headache frequency/month: 5–15 Major medical illness under treatment
Headache history > 2 years Pregnancy
Willing to complete daily diary Clotting disorders
Able to attend 8 weekly treatments Head or neck trauma in past 2 years
Cranial/neck surgery in past 2 years
Cardiac Pacemaker
Other implanted or external electrical device (e.g. insulin pump)
*International Classification of Headache Disorders, defined by expert members of the International Headache SocietyBMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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Baseline Period
Eligible subjects are instructed in the maintenance of a
daily headache diary for eight consecutive weeks while
continuing usual care. Subjects have the option of com-
pleting the diary either on paper and mailing it to the
study coordinator, or on a secure internet website. After
they have completed 4 weeks of diaries, their entries are
reviewed with the study neurologist to determine eligibil-
ity for the treatment phase of the study. Eligibility consists
of completion of at least 80% of headache diaries and
report of at least 5 migraines. Eligible subjects are called
and scheduled to visit the therapist for eight weekly ses-
sions. They are asked to continue their headache diaries
for the full 20-week duration of the study.
Randomization
Subjects are randomized to one of the two treatment arms
using a concealed allocation protocol. At the subject's first
treatment visit, the study therapist performs a brief intake
interview and then opens an opaque, sequentially num-
bered envelope that identifies which treatment group has
been randomly selected for this subject. The randomiza-
tion scheme uses a permuted block method to generate
the intervention assignment sequence being implemented
at the treatment location to assure that the randomization
balance is maintained throughout enrollment [24].
Study therapist
The study therapist, Laurel J. Wilkinson, is a NC licensed
massage and body therapist and registered nurse. She
trained in CST under John E. Upledger, M.D. in Michigan
in 1979–1980 and then completed advanced CST training
at the Upledger Institute [Upledger Institute, 11211 Prosper-
ity Farms # D325, Palm Beach Gardens, FL 33410] from
1986–1989. Ms. Wilkinson has utilized CST full-time in
her practice for the past 18 years. She is an approved
Upledger Institute Instructor for CST classes.
We chose to use only one therapist because, with training
and close monitoring, we theorized that a single experi-
enced individual was more likely to achieve a standard-
ized approach to each subject than several therapists in a
modality where only weak reliability between practition-
ers in diagnosis and palpation techniques has been
reported [25-27]. Also, there is evidence that using more
than one CST therapist in a study can dilute the outcome
effect [28].
To evaluate possible therapist bias, half of all encounters
with subjects are videotaped. Selected recordings are ana-
lyzed qualitatively to assess for any systematic differences
in her interactions with subjects in the two groups.
Masking
Because of the nature of the interventions, the therapist
and subjects cannot be masked. In addition, those indi-
viduals on the study team who review the video tapes are
unmasked. Other study personnel may learn of treatment
assignment in the course of reviewing diaries or other
data. Because the study neurologist conducts post treat-
ment exit interviews with the subjects, his masking is bro-
ken at that time. Only the biostatistician is completely
unaware of the treatment assignment.
The Intervention Group – CST
Subjects in the intervention group receive usual medical
care plus one CST treatment per week for 8 weeks. Because
no studies have reported usual or evidence-based treat-
ment schedules for CST, the number of treatments was
based on data from our initial, unpublished CST practi-
tioner survey and opinions of experienced therapists in
the field. The subject lies supine and fully clothed, except
for belts, watches, and shoes, while the therapist proceeds
with an evaluation of the craniosacral system. She then
assesses and treats connective tissue restrictions of the
lower and upper body, the neck, all of the cranial bones
and underlying tissues.
The CST protocol for each subject follows the Upledger
Institute approach using the elements shown in Table 2.
The therapist keeps detailed notes on an assessment and
treatment form developed for the study. Because CST may
vary among individual migraine patients based on the
therapist's assessment, complete standardization of the
treatment protocol was not possible. The therapist may
elect to work on any fascial restrictions she finds, as in an
ankle or shoulder. At each visit, the protocol calls for a
symptom history covering the previous week, blood pres-
sure and heart rate determinations before and after treat-
ment, and a summative global assessment of the
craniosacral system (CSF rhythm and points of restricted
movements).
The Attention Control Group – Low strength static 
magnets (LSSM)
We selected low strength static magnet (LSSM) therapy as
the control intervention on the basis that it was a recog-
nized and popular alternative treatment for pain syn-
dromes, had a valid biological rationale and would
probably provoke similar expectations of healing.
The LSSM protocol was developed and tested over six
months. First, the therapist was videotaped to establish
the sequence of activities for subjects undergoing crani-
osacral and magnet therapy. A standardized sequence of
CST was developed to permit a similarity of treatment
among the CST subjects. The LSSM protocol was designed
to mimic the CST protocol in terms of length of treatmentBMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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sessions, sequence of interactions with the therapist, and
overall treatment experience. During treatment, the sub-
ject lies supine on a table surrounded by small magnets,
half of which are completely inactive. The active magnets
are positioned such that they exert no field strength on the
subject's skin or body. At each visit, the therapist confirms
this by measuring the strength of the magnets with a
Gaussmeter [DC Magnetometer, Model 1, AlphaLab, Inc.,
1280 South 300 West, Salt Lake City, UT 84101]. Gaussm-
eter readings are designed to both improve the believabil-
ity of the therapy and give the therapist something to do
during the magnet sequence.
To further enhance active therapist involvement and sim-
ulate the CST maneuvers, additional inactive magnets
contained within moveable pads are positioned on the
subject in the same body areas treated in the CST protocol
and moved to different sites at similar intervals.
The therapist then practiced the protocol every two weeks
for 3 months to achieve a level of comfort with it that
would approximate her comfort in administering CST.
Although the therapist does not believe that magnet ther-
apy will be effective, she is able to mask her doubts. In the
videotaped encounters, we see her giving subjects copies
of articles endorsing magnet therapy and we hear her
explaining a plausible rationale for its efficacy.
A sham CST intervention was rejected as unfeasible. First,
since the mechanism of CST is not completely known, it
is unclear whether a sham procedure might exert a specific
and unmeasurable therapeutic benefit [29]. Second, we
suspected that an experienced CST practitioner would
have difficulty in deviating from long established clinical
skills and could not effectively perform sham maneuvers
involving tissue palpation and release intended to parody
CST. Furthermore, training an alternative therapist naïve
to CST to perform a sham CST maneuver might be diffi-
cult and would introduce therapist variability into the
randomization process [28].
Outcome measures and study instruments
Primary outcome variables
The primary outcome variables assessed for this study
include headache-specific quality-of-life, frequency of
headache and self perceived benefit of the intervention
(Table 3 describes measurement points for these varia-
bles). Detailed descriptions of these variables follow:
Headache Impact Test (HIT-6)
Headache-specific quality of life is measured as the
change in headache-related disability at 8 weeks after ran-
domization as assessed by the HIT-6. The HIT-6 is a vali-
dated questionnaire designed "to measure the impact
headaches have on a person's ability to function on the
job, at school, at home, and in social situations" [30]. It
has good internal reliability [31]. The scale consists of six
items that cover various content areas relevant to head-
ache-related disability: pain, social functioning, role func-
tioning, vitality, cognitive functioning, and psychological
distress. A decrease of 2.3 HIT points (95% CI, 0.3 to 4.3)
over six weeks among patients with chronic headache cor-
responds to a "somewhat better" self-reported rating on a
global clinical change scale [31].
Table 2: Summary of procedural sequence at each visit for craniosacral therapy (CST), 2007–2008
1. Brief review of recent headache symptoms and general symptoms and assessment of any adverse effects of treatment
2. Evaluation of the craniosacral rhythm*, including amplitude, quality, and rate
3. Arcing, palpating for active lesions – checking for fascial restrictions†
4. Fascia releases at pelvis, dural tube traction, L5-S1 decompression, sacro-iliac decompression§
5. Fascia releases at lower respiratory, thoracic inlet, hyoid, and cranial base
6. Vertical membrane (falx cerebri) system evaluation and treatment using frontal and parietal bone and soft tissue manipulations
7. Horizontal membrane system (tentorium) evaluation and treatment using sphenoid and temporal bone and soft tissue manipulations
8. Mandibular compression and decompression
9. Hard palate intra-oral evaluation and treatment
a. illary-palatine: flexion/extension, torsion, shear, compression
b. vomer evaluation: flexion/extension, torsion, shear, compression
c. palatine
d. zygoma and nasal bones
10. Dural tube evaluation – mobility, tension and restrictions#
11. Still-point induction**
12. Global assessment with percentage improvement
* The craniosacral rhythm is palpated by the practitioner (at the feet) and assessed for rate, quality, and symmetry. A normal rate is 8–12 cycles per 
minutes. A normal rhythm shows a balanced vitality.
† Arcing is a gentle traction technique for detecting fascial restrictions.
§ Decompression allows for the release of joint and soft-tissue restrictions.
# Dural tube, the sheath of connective tissue surrounding the spinal cord, is evaluated through manual palpation of the spine between the occiput 
and the sacrum.
** Still point induction is a manual technique performed at the occiput, designed to bring the craniosacral rhythm to a therapeutic pause.BMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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Headache frequency
the second primary outcome variable, is determined from
the daily headache diary as the total number of headache
hours during a 24-hour period. A second dimension of
headache frequency is measured by the proportion of
headache-free days experienced by a study participant
(Figure 2). After receiving careful instruction, subjects
record the presence and intensity of their headaches on an
hourly basis. Subjects are also invited to comment on the
nature of their headaches, the associated symptoms, and
the suspected triggers.
Self-perceived benefit
of the intervention, one aspect of Specific Aim 3, is meas-
ured at the end of the 8-week treatment period. Subjects
rate the perceived benefit of the therapy on a five point
scale ranging from "greatly worsened my clinical condi-
tion" to "greatly improved my clinical condition". In
addition, they assess the therapy as "more harmful than
helpful", "neither harmful nor helpful", or "more helpful
than harmful".
Secondary outcome variables
Secondary outcome variables include the following: head-
ache intensity, headache-associated symptoms, medica-
tion used, cost of medication, health care utilization,
change in general health status, study credibility, degree of
headache related disability (MIDAS), and satisfaction
with care. These are discussed below.
Headache intensity
As noted, the headache diary captures headache frequency
and intensity, as well as other information. Intensity is
defined as mild, moderate, or severe. Guides to grading
headache intensity are included with each diary. The total
hours of moderate or severe headache during a 24-hour
period will serve as the measure of intensity. Subjects are
invited to comment on the nature of their headaches, the
associated symptoms, and the suspected triggers.
Headache-associated healthcare utilization
The diary also captures medication use and visits with a
health care provider. (Figure 2).
Functional status and general health-related quality of life
The Medical Outcomes Study Short Form (SF-36) is a
widely-used functional status instrument that assesses
eight different health domains: physical functioning; bod-
ily pain; role limitations due to physical problems; role
limitations due to emotional problems; general mental
health; social functioning; vitality; and general health per-
ceptions [32]. A daily measure of well-being is included in
the daily headache diary.
Table 3: Summary of Measures and Timing of Administration for Clinical Feasibility Trial of Craniosacral Therapy, 2006–2008
Week 0 Weeks 1 to 8 Weeks 8 to 16 Weeks 16 to 20
Variable or Instrument Baseline 
Assessments
Baseline with Usual 
Care
Usual Care plus CST or 
LSSM
Post-treatment 
Assessments
Demographic/Clinical Data Week 0
ICHD* Diagnosis Week 0
Functional status – MOS SF-36 Week 0 Week 20
Expectation of benefit/Credibility † (post 1st treatment)
Headache QOL – HIT-6 § Week 0 Week 8 Week 16
Headache Diary: Frequency Daily Daily
Perceived clinical change Week 8 Week 16
Headache disability – MIDAS # Week 0 Week 20
Headache Diary: Intensity and 
Duration
Daily Daily Daily
Headache Diary: Medication Use/
Cost
Daily Daily Daily
Headache Diary: Health care visits Daily Daily Daily
Satisfaction with care Week 0 Week 8 Weeks 16, 20
Blood pressure and heart rate Week 0 Weekly
Therapist – Subject Interaction 
Analysis Videotaping Encounters**
Weeks 9,11, 13 & 15
* International Classification of Headache Disorders, defined by expert members of the International Headache Society
† Based on a measure developed by Borkovec and Nau to measure credibility of psychological interventions [38,39].
§ Headache Impact Test was developed to measure headache-related quality of life [33].
# Migraine disability assessment score assesses the number of days of missed work or school in the past 3 months [36,37].
† Noldus 'Observer' Video-Pro System software facilitates the analysis of videotaped behaviors [42,43].BMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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Headache-related disability: MIDAS
Disability, defined as the consequences of illness on abil-
ity to work and function, is measured using the migraine
disability assessment score (MIDAS). Derived from the
Headache Impact Test, MIDAS is a 7-item questionnaire
that assesses the number of days during the previous three
months that respondents missed work or school, experi-
enced decreased productivity at work or home, or missed
social engagements because of headaches. Test-retest reli-
ability is acceptable, with Spearman's correlation coeffi-
cient ranging from 0.67 to 0.73. Cronbach's alpha is 0.83
[33,34].
On-line Daily Headache Diary of the Clinical Feasibility Trial of Craniosacral Therapy (CST), 2006–2008 Legend: Subjects had  the option of filling out the diary on paper or on line Figure 2
On-line Daily Headache Diary of the Clinical Feasibility Trial of Craniosacral Therapy (CST), 2006–2008 Leg-
end: Subjects had the option of filling out the diary on paper or on line. Detailed instructions were provided at the 
time of enrollment.
Study ID: __________  Diary for this day:__________Month:___Day:___Year:_______
Definitions of mild, moderate and severe headaches 
Mild:  (a) Your pain requires less than two doses of over the counter medication per 12 hours; (b) you are able to 
function at an 80% level or more; (c) you have minimal nausea or sensitivity to light or sound; (d) on a scale of 1-10, 
with 1=minimal pain and 10=worst pain ever, your pain is a 1, 2 or 3. You may or may not experience an aura with 
your headache. 
Moderate: (a) Your pain requires over the counter or prescription medication every 3 to 4 hours; (b) you are able to 
function at an 50% level or more; (c) you have mild to moderate nausea or sensitivity to light or sound; (d) on a scale 
of 1-10, with 1=minimal pain and 10 worst pain ever, your pain is a 4, 5 or 6. You may or may not experience an aura 
with your headache. 
Severe: (a) Your pain requires maximal available pain medication every 3-4 hours; (b) your ability to function is less 
than 50%; (c) you have significant nausea or sensitivity to light or sound; (d)  on a scale of 1-10, with 1=minimal pain 
and 10=worst pain ever, your pain is a 7, 8, 9 or 10.  You may or may not experience an aura with your headache. 
Time 
     of 
headache
None Mild Moderate Severe Sleeping
12 MN - 1 AM 
1 AM - 2 AM 
And every hour 
until…
11 PM- 12 MN 
If you had a headache today, did you have an aura with it? 
 Yes  No 
Name of Medicine:_____________________.  Number of doses taken:  ______ 
Name of Medicine:_____________________.  Number of doses taken:  ______ 
Name of Medicine:_____________________.  Number of doses taken:  ______
Did you visit a health professional today? 
 No  Yes 
If you visited a health professional today, what type?
 Family doctor  Neurologist  Therapist  ER  Other:_____________ 
Please rate your overall health today: 
 Poor  Fair  Good         Excellent
Comments:
Record your diary informationBMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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Control variables
Control variables include socio-demographic and clinical
characteristics, as well as evaluation of subject bias and
protocol variability. These are described below.
Socio-demographic and clinical characteristics
Age, gender, ethnicity, religion, occupation, employment
status, level of education, income, type of medical insur-
ance, date of onset of migraine, history of use of CST, and
presence of other medical conditions and diagnoses are
collected at the time of the baseline interview. The medi-
cal history and physical exam performed by the PI are part
of this data set. Subject weight, height, and vital signs are
measured at the baseline visit.
Evaluation of Subject Bias and Protocol Variability
Credibility and Expectation of Benefit
Subject credibility and expectations are assessed using an
instrument adapted from a validated scale developed by
Borkovec and Nau [35,36]. The instrument is adminis-
tered just before the second visit. Data analysis will dem-
onstrate whether subjects in the two groups have similar
or different expectations of benefit. It has been shown that
high expectations of treatment are closely related to better
outcomes [37,38].
Quality control
Videotapes of the first, third, fifth, and seventh treatment
sessions are used to provide feedback to the therapist to
ensure standardization of the CST and LSSM treatment
protocols as well as to identify any differences in thera-
pist-subject behavioral interactions between the CST and
LSSM treatments and thus control for interactional bias.
Noldus 'Observer' Video-Pro System programmable soft-
ware is used to code and analyze the selected videotaped
sessions and quantitatively assess specific therapist and
subject behaviors [39,40].
Adverse events
Reports of adverse events are obtained from subjects at
each treatment session, from self reports recorded in the
headache diaries or by direct contact with study staff.
Adverse events are investigated by the study neurologist
and are reported both to the UNC Institutional Review
Board and the National Institutes of Health.
Analytic Strategy
Sample size and power calculations are based on the
assumptions regarding the changes under treatment in
two key measures of interest, namely, quality of life as
measured by the Headache Impact Test (HIT) and head-
ache frequency based on headache diary. Preliminary
studies [41] have shown a mean HIT score of 63.7 with a
standard deviation of 5.2 among migraine patients. Keep-
ing the control values of HIT at this level, we estimate that
with 45 subjects in each arm the study will have 80%
power to detect a 3.5 points change in the HIT score.
Based on our clinical experience we also estimate that, on
average, migraine patients experience two headaches per
week. With 45 patients per group, the study will have 80%
power to detect a reduction in the headache frequency to
one per week.
Regression modeling strategies will be used to test the pri-
mary hypothesis. A simple linear regression model with
the HIT score at end of the study (16 weeks) controlling
for HIT score at the baseline will be used to test for signif-
icant treatment effects. We will use repeated measures
analysis on HIT measures to detect whether the change in
HIT scores are significantly different between the two
groups. Because of the correlated nature of the repeated
measures, regression models using a generalized estimat-
ing equations (GEE) approach will be used to test the
hypothesis of change. A significant time and treatment
interaction will detect significant changes in the score. A
similar analysis strategy using GEE methods will be used
to analyze daily records of headache. All data analysis will
be performed on an intent-to-treat basis. The GEE method
assumes that missingness in data are completely at ran-
dom. Under the missing at random assumption, it is pos-
sible to conduct analysis using multiple imputation
procedures [42].
Results
Recruitment into the study has proceeded as planned
(Table 4). The majority of subjects are self-referred, having
heard of the study either through email, flyers, or from a
friend or family member. We have had mixed success in
recruiting minorities for the study. Advertisements in the
Spanish print media and in clinics serving minority pop-
ulations were added to increase recruitment among the
underserved. In addition, our Hispanic research assistant
has helped us to recruit representative numbers of His-
panic subjects through personal contacts. Despite adding
an African-American research assistant to the team, we
have had less success recruiting African Americans.
At this time, 169 individuals have been screened for eligi-
bility of which 109 were eligible to take part in the study.
Five did not qualify during the baseline phase because of
inadequate headache frequency. Nineteen have with-
drawn from the study after giving consent. So far, seven
subjects have failed to complete their headache diaries.
Other subjects have dropped out due to intercurrent med-
ical problems, accidents, or changes in conventional med-
ication. No subject has dropped out due to an adverse
event. So far, there has been equal drop out between
groups after randomization.BMC Complementary and Alternative Medicine 2008, 8:28 http://www.biomedcentral.com/1472-6882/8/28
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Well over half of our subjects have adhered to completing
a data-rich daily diary, either online or on paper, with
minimal attrition. So far, we have lost 16% of subjects due
to an inability to keep up with daily diary entry. Since the
online diaries have been available, 86% have chosen to
use them; 14% have chosen the paper diaries.
We have found that the online diary is superior to the
paper diary for several reasons: (1) Missing data on the
online diaries can be identified earlier and subjects can be
prompted to remedy it. The paper diary is completed
weekly and mailed in; it is not feasible to have subjects
correct missing days once mailed to us. (2) Online diary
data goes directly into a text file. Although there is still a
potential for subject input error, this method eliminates
the errors of secondary data entry. The time required for
secondary data input is also eliminated. (3) Perhaps
because they can type into it, subjects add more com-
ments to the online diaries. We believe this provides a
richer data set. (4) Finally, the online diaries are easier to
copy. Several of our subjects have asked for a copy of the
diary to share with their provider. Their individual diaries
can be extracted from the online diary and sent to them at
the end of their participation in the study.
Discussion
Migraine is a common condition associated with signifi-
cant disability [2]. Because pharmaceuticals for migraine
provide incomplete relief of symptoms and are associated
with significant side effects, many individuals seek com-
plementary therapies, such as CST. Up to now, CST has
not been studied rigorously. This report supports the fea-
sibility of undertaking a rigorous randomized clinical trial
of CST for migraine, using a standardized CST protocol
and an innovative control protocol developed for this
study.
In any study of complementary therapy in which there is
the likelihood of a substantial placebo and expectation
effect, a methodology is needed that permits detailed eval-
uation of the interaction between therapist and subject.
We find that the Noldus system of interactional analysis
using videotapes of the treatment sessions is a feasible,
though time consuming, technique for achieving this
goal. A detailed analysis of the videotapes will lead to
refinements of the control (LSSM) protocol such that it
more closely matches the intervention (CST) in terms of
credibility and expectations of benefit. In addition, a qual-
itative evaluation of the post-intervention interview will
yield important information about subject's satisfaction
with the therapies.
We have established that it is possible to recruit enough
subjects with migraine to obtain comparison groups with
sufficient analytic power, though an enrollment period of
18 months would be needed to obtain at least 45 subjects
in each group. Our data analyses, comparing CST with
LSSM will allow us to determine effect sizes appropriate
for a larger, definitive trial.
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